Prospective treatment of age-related diseases by slowing down aging
- PMID: 22841821
- DOI: 10.1016/j.ajpath.2012.06.024
Prospective treatment of age-related diseases by slowing down aging
Abstract
Atherosclerosis, hypertension, obesity, diabetic complications, cancer, benign prostate hyperplasia, Alzheimer and Parkinson diseases, age-related macular degeneration, osteoarthritis, osteoporosis, and seborrheic keratosis are strongly associated with aging, implying a common underlying process. Each disease is treated separately and, in most cases, symptomatically. Suppression of aging itself should delay or treat all age-related diseases, thus increasing healthy life span and maximal longevity. But, is it possible to slow down aging? Recent evidence indicates that the target of rapamycin signaling pathway is involved in cellular senescence and organismal aging. Preclinical and clinical studies demonstrated the therapeutic effects of rapamycin in diverse age-related diseases. One simple reason why a single drug is indicated for so many age-related diseases is that it inhibits the aging process.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition.Cell Cycle. 2006 Sep;5(18):2087-102. doi: 10.4161/cc.5.18.3288. Epub 2006 Sep 15. Cell Cycle. 2006. PMID: 17012837 Review.
-
An anti-aging drug today: from senescence-promoting genes to anti-aging pill.Drug Discov Today. 2007 Mar;12(5-6):218-24. doi: 10.1016/j.drudis.2007.01.004. Epub 2007 Feb 9. Drug Discov Today. 2007. PMID: 17331886 Review.
-
Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats.Am J Pathol. 2012 Aug;181(2):472-7. doi: 10.1016/j.ajpath.2012.04.018. Epub 2012 Jun 7. Am J Pathol. 2012. PMID: 22683466
-
Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases.Rejuvenation Res. 2011 Aug;14(4):437-41. doi: 10.1089/rej.2011.1238. Rejuvenation Res. 2011. PMID: 21851176 Review.
-
From rapalogs to anti-aging formula.Oncotarget. 2017 May 30;8(22):35492-35507. doi: 10.18632/oncotarget.18033. Oncotarget. 2017. PMID: 28548953 Free PMC article. Review.
Cited by
-
Recent Advances in Nanoencapsulation Systems Using PLGA of Bioactive Phenolics for Protection against Chronic Diseases.Int J Environ Res Public Health. 2019 Dec 6;16(24):4962. doi: 10.3390/ijerph16244962. Int J Environ Res Public Health. 2019. PMID: 31817699 Free PMC article. Review.
-
TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.Cell Death Dis. 2013 Dec 12;4(12):e964. doi: 10.1038/cddis.2013.506. Cell Death Dis. 2013. PMID: 24336084 Free PMC article. Review.
-
Geroconversion: irreversible step to cellular senescence.Cell Cycle. 2014;13(23):3628-35. doi: 10.4161/15384101.2014.985507. Cell Cycle. 2014. PMID: 25483060 Free PMC article. Review.
-
The hyperfunction theory of aging: three common misconceptions.Oncoscience. 2021 Sep 17;8:103-107. doi: 10.18632/oncoscience.545. eCollection 2021. Oncoscience. 2021. PMID: 34549076 Free PMC article. No abstract available.
-
DNA- and telomere-damage does not limit lifespan: evidence from rapamycin.Aging (Albany NY). 2021 Feb 12;13(3):3167-3175. doi: 10.18632/aging.202674. Epub 2021 Feb 12. Aging (Albany NY). 2021. PMID: 33578394 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical